EMEA-002536-PIP01-18-M01
Key facts
| Active substance |
Lebrikizumab
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0286/2021
|
| PIP number |
EMEA-002536-PIP01-18-M01
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of atopic dermatitis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Dermira Inc.
Tel.: +1 8773375552 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|